Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O-TIE maintenance in high-risk rhabdomyosarcoma and RMS-like soft tissue sarcoma
NCT00876031Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2009
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of trofosfamide, idarubicin and etoposide in rhabdomyosarcoma (RMS) and soft tissue sarcoma (STS), sponsored by University Hospital Tübingen. Primary endpoint: Event-Free Survival at 3 years. Started Jul 2009; status: completed.
02
Drugs
trofosfamideidarubicinetoposide
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00876031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00876031.